Cercar
01/09/2021
Hyporesponsiveness or resistance to the action of parathyroid hormone in chronic kidney disease
Bover, J, Arana, C, Urena, P, Torres, A, Martin-Malo, A, Fayos, L, Coll, V, Lloret, MJ, Ochoa, J, Almaden, Y, Guirado, L, Rodriguez, M. Hyporesponsiveness or resistance to the action of parathyroid hormone in chronic kidney disease. NEFROLOGIA. 2021; 41(5)DOI:10.1016/j.nefro.2020.12.019. PMID:33985858. IF:3.084(Q2/5D).
01/07/2023
Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes
Hughes, DA, Bichet, DG, Giugliani, R, Hopkin, RJ, Krusinska, E, Nicholls, K, Olivotto, I, Feldt-Rasmussen, U, Sakai, N, Skuban, N, Sunder-Plassmann, G, Torra, R, Wilcox, WR. Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes. JOURNAL OF MEDICAL GENETICS. 2023; 60(7)DOI:10.1136/jmg-2022-108669. PMID:36543533. IF:3.600(Q2/3D).
01/06/2023
Post-transplant diabetes mellitus and renal cell cancer after renal transplantation
Porrini, E, Perez, NM, Diaz, JM, Lauzurrica, R, Rodriguez, JO, Torres, IS, Moreso, F, Garrit, JMC, Ruiz, RB, Vilaro, MI, Lima, MXM, Ramchand, SK, Ruiz, JC, de los Rios, FG, Alvarez, CR, Guindo, MDD, Macias, M, Vela, DB, Osuna, A, Bayes-Genis, B, Sanchez, CA, Ruiz, MD, Rodriguez, AER, Rollan, RD, Rinne, FG, Sosa, AJ, Mallen, PD, Rinne, AG, Miranda, DM, Torres, A. Post-transplant diabetes mellitus and renal cell cancer after renal transplantation. NEPHROLOGY DIALYSIS TRANSPLANTATION. 2023; 38(6)DOI:10.1093/ndt/gfac291. PMID:36323457. IF:4.800(Q1/2D).
04/04/2023
Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment
Rodriguez-Espinosa, D, Broseta, JJ, Bastida, C, Alvarez-Mora, MI, Nicolau, C, Alvarez, C, Agraz-Pamplona, I, Sanchez-Baya, M, Furlano, M, Ruiz, C, Quintana, LF, Pineiro, GJ, Poch, E, Torra-Balcells, R, Blasco, M. Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment. NEPHRON. 2023; 147(3-4)DOI:10.1159/000526368. PMID:36088902. IF:2.300(Q2/5D).
24/01/2023
The 2019 and 2021 International workshops on Alport syndrome (vol 30, 507, 2022)
Daga S., Ding J., Deltas C., Savige J., Lipska-Zietkiewicz B.S., Hoefele J., Flinter F., Gale D.P., Aksenova M., Kai H., Perin L., Barua M., Torra R., Miner J.H., Massella L., Ljubanovic D.G., Lennon R., Weinstock A.B., Knebelmann B., Cerkauskaite A., Gear S., Gross O., Turner A.N., Baldassarri M., Pinto A.M., Renieri A.. The 2019 and 2021 International workshops on Alport syndrome (vol 30, 507, 2022). EUROPEAN JOURNAL OF HUMAN GENETICS. 2023; 32(1)DOI:10.1038/s41431-023-01286-z. PMID:36690832. IF:3.700(Q2/3D).
09/01/2023
The Spanish Fabry women study: a retrospective observational study describing the phenotype of females with GLA variants
Sánchez R., Ripoll-Vera T., López-Mendoza M., de Juan-Ribera J., Gimeno J.R., Hermida Á., Ruz-Zafra M.A., Torregrosa J.V., Mora A., García-Pinilla J.M., Fortuny E., Aguinaga-Barrilero A., Torra R.. The Spanish Fabry women study: a retrospective observational study describing the phenotype of females with GLA variants. Orphanet Journal of Rare Diseases. 2023; 18(1)DOI:10.1186/s13023-022-02599-w. PMID:36624527. IF:3.400(Q2/4D).